SEARCH

SEARCH BY CITATION

References

  • 1
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edn. Washington, DC: APA, 1994.
  • 2
    Kessler RC, Berglund P, Demler O, Jin R, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593602.
  • 3
    Kessler RC, Tat Chiu W, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey. Arch Gen Psychiatry 2005;62:617627.
  • 4
    Bruce SE, Yonkers KA, Otto MW et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005;162:11791187.
  • 5
    Feske U, Chambless DL. Cognitive behavioral versus exposure only treatment for social phobia: a meta-analysis. Behav Ther 1995;26:695720.
  • 6
    Gould RA, Buckminster S, Mark H, Michael W, Yap L. Cognitive-behavioral and pharmacological treatment for social phobia: a meta-analysis. Clin Psychol Sci Pract 1997;4:291306.
  • 7
    Fedoroff IC, Taylor S. Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol 2001;21:311324.
  • 8
    Taylor S. Meta-analysis of cognitive-behavioral treatments for social phobia. J Behav Ther Exp Psychiatry 1996;27:19.
  • 9
    Hood S, Nutt D. Psychopharmacological treatments: an overview. In: CrozierWR, AldenL, eds. International handbook of social anxiety. Chichester: Wiley, 2001:471504.
  • 10
    Blanco C, Schneier F, Schmidt A, Blanco-Jerez CR, Sanchez-Làcay A. Pharmacological treatment of social anxiety disorder: A meta-analysis. Depress Anxiety 2003;18:2940.
  • 11
    Blanco C, Raza MS, Liebowitz M. The evidence-based pharmacological treatment of social anxiety disorder. Int J Clin Neuropsychopharmacol 2003;6:427442.
  • 12
    Davidson R, Foa E, Huppert J et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalised social phobia. Arch Gen Psychiatry 2004;61:10051013.
  • 13
    Liebowitz MR, Heimberg RG, Schneier FR et al. Cognitive-behavioral group therapy versus phenelzine in social phobia: long-term outcome. Depress Anxiety 1999;10:8998.
  • 14
    Haug TT, Blomhoff, S, Hellstrom K et al. Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomised controlled trial. Br J Psychiatry 2003;182:312318.
  • 15
    Juster HR, Heimberg RG. Social phobia. Longitudinal course and long-term outcome of cognitive-behavioral treatment. Psychiatr Clin North Am 1995;18:821842.
  • 16
    Rodebaugh T, Holaway R, Heimberg R. The treatment of social anxiety disorders. Clin Psychol Rev 2004;24:883908.
  • 17
    Turner SM, Beidel DC, Wolff PL, Spaulding S, Jacob RG. Clinical features affecting treatment outcome in social phobia. Behav Res Ther 1996;34:795804.
  • 18
    Mörtberg E, Berglund G, Sundin Ö. Intensive cognitive behavioural group treatment for social phobia: a pilot study. Cognit Behav Ther 2005;34:4149.
  • 19
    Mörtberg E, Karlsson A, Fyring C, Sundin Ö. Intensive cognitive-behavioural group treatment of social phobia (CBGT): a randomised controlled study. J Anxiety Disord 2006;20:646660.
  • 20
    Clark DM, Ehlers A, McManus F et al. Cognitive therapy vs. fluoxetine plus self exposure in the treatment of generalized social phobia (social anxiety disorder): a randomized placebo controlled trial. J Consult Clin Psychology 2003;71:10581067.
  • 21
    Stangier U, Heidenreich T, Peitz M, Lauterbach W, Clark DM. Cognitive therapy for social phobia: individual versus group treatment. Behav Res Ther 2003;41:9911007.
  • 22
    Clark DM, Ehlers A, Hackmann A et al. Cognitive therapy versus exposure and applied relaxation in social phobia: a randomized controlled study. J Consult Clin Psychology 2006 (in press).
  • 23
    First BM, Spitzer RL, Gibbon M, Williams JBW. Users guide for the Structured Clinical Interview for DSM-IV Axis I Disorders: SCID-I Clinician Version. Washington, DC: American Psychiatric Press, 1995.
  • 24
    Hjelm-Karlsson K. Using the biased coin design for randomization in health care research. West J Nursing Res 1991;13:285288.
  • 25
    Clark DM, Wells A. A cognitive model of social phobia. In: HeimbergMR, LiebowitzM, HopeDA, SchneierFR, eds. Social phobia: diagnosis, assessment and treatment. New York: Guilford press, 1995:6993.
  • 26
    Kåver A. Social Fobi-Att känna sig granskad och bortgjord. Stockholm: Cura Bokförlag och Utbildning AB Stockholm, 1999.
  • 27
    ÖSt LG. Tillämpad avslappning – behandlingsmanual (Applied relaxation – treatment manual). Stockholm: Stockholms universitet Psykologiska Institutionen (Stockholm University, Department of Psychology), 1982.
  • 28
    Bouwer C, Stein DJ. Use of the selective serotonin reuptake inhibitor citalopram in treatment of generalized social phobia. J Affect Disord 1998;49:7982.
  • 29
    Ballenger J, Davidson J, Lecrubier Y et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 1998;59:5460.
  • 30
    Liebowitz MR. Social phobia. Mod Probl Pharmacopsychiatry 1987;22:141173.
  • 31
    Baker S, Heinrichs N, Kim H-J, Hofmann S. The Liebowitz Social Anxiety Scale as a self-report instrument: a preliminary psychometric analysis. Behav Res Ther 2002;40:701715.
  • 32
    Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive therapy of depression. New York: Guilford Press, 1979.
  • 33
    Beck AT, Steer RA. Beck depression inventory, Manual. Stockholm, Sweden: Psykologiförlaget, 1995.
  • 34
    Mattick RP, Clark JC. Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behav Res Ther 1998;36:455470.
  • 35
    Marks I, Mathews AM. Brief standard self-rating for phobic patients. Behav Res Ther 1979;17:263267.
  • 36
    Watson D, Friend R. Measurement of social-evaluative anxiety. J Consult Clin Psychology 1969;33:448457.
  • 37
    Rosenthal R, Rosnow RL. Essentials of behaviour research: methods and data analysis. New York: McGraw-Hill, 1991.
  • 38
    Olfson M, Fireman B, Weissman M, Leon A, Sheehan D, Kathol R. Mental disorders and disability among patients in primary care group practice. Am J Psychiatry 1997;154:17341740.
  • 39
    Gibbons R, Hedeker D, Elkin I et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Arch Gen Psychiatry 1993;50:739750.
  • 40
    Gueorguieva R, Krystal J. Move over anova. Progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 2004;61:310317.
  • 41
    Cohen J. Statistical power analyses for the behavioural sciences. Hillsdale, NJ: Erbaum, 1988.
  • 42
    Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychology 1991;59:1219.
  • 43
    Braga DT, Cordioli AV, Niederauer K, Manfro GG. Cognitive-behavioral group therapy for obsessive-compulsive disorder: a 1-year follow-up. Acta Psychiatr Scand 2005;112:180186.
  • 44
    Bechdolf A, Köhn D, Knost B, Pukrop R, Klosterkötter J. A randomized comparison of group cognitive-behavioural therapy and group education in acute patients with schizophrenia: outcome at 24 months. Acta Psychiatr Scand 2005;112:173179.
  • 45
    Ekselius L, Lindström E, Von Knorring L, Bodlund O, Kullgren G. SCID II interviews and the SCID screen questionnaire as diagnostic tools for personality disorders in DSM-III-R. Acta Psychiatr Scand 1994;90:120123.